Suppression of abnormal karyotype predicts superior survival in multiple myeloma

Leukemia

Volumn 22, Issue 4, 2008, Pages 850-855

  Arzoumanian, V ^a   Hoering, A ^b   Sawyer, J ^a   van Rhee, F ^a   Bailey, C ^a   Gurley, J ^a   Shaughnessy Jr , J D ^a   Anaissie, E ^a   Crowley, J ^b   Barlogie, B ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; HAZARD RATIO; HUMAN; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 42349086511     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405091     Document Type: Article

References (31)

1. Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. Plasma cell karyotype in multiple myeloma. Blood 1988; 71: 453-456.
2. Tricot G, Barlogie B, Jagannath S,-Bracy D, Mattox S, Vesole DH et al Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995; 86: 4250-4256.
3. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S et al. The unique role of cytogenetits in the prognosis of patients with myeloma receiving high dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659-2666.
4. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998; 101: 189-195.
5. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A et al. Predicting long-term (≥5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116: 211-217.
6. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): Only 13% 1-year survival despite tandem transplants. Br J Haematol 2003; 122: 430-440.
7. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al Results of high-dose therapy for 1000 patients with multiole myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
8. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of MM: A workshop report. Cancer Res 2004; 64: 1546-1558.
9. Shaughnessy, J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F et al Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in multiple myeloma treated with Total Therapy I; interpretation in the context of global gene expression Blood 2003; 101: 3849-3856.
10. Barlogie B, Alexanian R, Pershouse M, Smallwood L, Smith L. Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest 1985; 76: 765-769.
11. Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M et al. Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluoresoence in situ hybridization. Cancer Res 1995; 55: 3854-3859.
12. Shaughnessy J, Tian E, Sawyer J, Bumm, K, Landes R, Badros A Sawyer J et al. High incidence of chromosome 13 deletions in multiple myeloma detected by multiprobe interphase FISH. Blood 2000; 96: 1505-1511.
13. Shaughnessy Jr J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haematol 2003; 120: 44-52.
14. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S Colla S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
15. Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276-2284.
16. Shaughnessy Jr JD, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: Superiority of molecular genetics. Br J Haematol 2007; 137: 530-536.
17. Haessler I, Shaughnessy ID, Zhan F, Crowley I, EPstein I, van Rhee F et al. Benefit of Complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7073-7079.
18. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A et al. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): Only 13% 1-year survival despite tandem transplants. Br J Haematol 2003; 133: 430-440.
19. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
20. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
21. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158-164.
22. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
23. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
24. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3. Br J Haematol 2007; 138: 176-185.
25. Pineda M, Zangari M, Haessler J, Anaissie E, Tricot J, van Rhee F et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: Comparison with total therapy 2. Br J Haematol (in press).
26. Pineda M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F et al. The Arkansas experience since 1989 in 3077 patients. Cancer (in press).
27. Sawyer J, Waldron J, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41-49.
28. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
29. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
30. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc, Series B 1972; 34: 187-220.
31. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.